AuthorCitation

Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

Hobday, Timothy J. , Mahoney, M. R. , Erlichman, Charles , Lloyd, R, Kim, G., Mulkerin, Daniel , Fitch, Tom R., Donehower, Ross C. , Picus, Joel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 4083-4083

10.1200/jco.2005.23.16_suppl.4083

A phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): A clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) Study

Erlichman, Charles , Goldberg, Richard M. , Mahoney, M. R. , Kabat, Brian, Huntington, Jefrey L., Sebo, Thomas J., Egner, James R., Pitot, Henry C., Sargent, Daniel J. , Kaufmann, Scott H.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 4026-4026

10.1200/jco.2005.23.16_suppl.4026

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

Kozloff, M., Cohn, Allen Lee, Christiansen, N., Flynn, Patrick J. , Kabbinavar, Fairooz F. , Robles, Robert, Sarkar, Somnath , Hambleton, J., Yood, Marianne Ulcickas , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3566-3566

10.1200/jco.2005.23.16_suppl.3566

Cost-effectiveness projections of FOLFOX vs. IFL in first-line therapy of metastatic colorectal cancer in the context of the U.S. health care system

Hillner, Bruce E., Fuchs, Charles S. , Goldberg, Richard M. , Schrag, Deborah , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3531-3531

10.1200/jco.2005.23.16_suppl.3531

Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)

Malik, Imtiaz A. , Hecht, J. Randolph, Patnaik, A., Croghan, Gary A., Navale, Lynn, MacDonald, Michael R. , Jerian, S., Meropol, Neal J. , Patnaik, Amita , Venook, Alan P. , Berlin, Jordan D.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3520-3520

10.1200/jco.2005.23.16_suppl.3520

Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chem

Rowland, Kendrith M. , Pitot, Henry C., Philip, P. A., Mitchell, Edith P. , Mailliard, J A, Goldberg, Richard M. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3519-3519

10.1200/jco.2005.23.16_suppl.3519

Endpoints for Colon Adjuvant Clinical Trials (CACT): Recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials

Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3512-3512

10.1200/jco.2005.23.16_suppl.3512

Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity

Grothey, Axel, McLeod, H. L., Green, E. M., Ramanathan, Rajesh , Findlay, B., Goldberg, Richard M. , Green, E. M., Sargent, Daniel J. , Fuchs, C., Williamson, Stephen K.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3509-3509

10.1200/jco.2005.23.16_suppl.3509

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis

Arkenau, Hendrik‐Tobias , Kubicka, Stefan, Kretzschmar, Albrecht , Freier, Werner , Seufferlein, Thomas , Hinke, Axel , Porschen, Rainer, Schmoll, Hans‐Joachim , Graeven, Ullrich , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3507-3507

10.1200/jco.2005.23.16_suppl.3507

A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

Adjei, Alex A. , Mandrekar, Sumithra J. , Marks, Randolph S., Hanson, L., Aranguren, Dawn, Jett, James R., Simantov, Ronit, Croghan, Gary A., Schwartz, Brian E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3067-3067

10.1200/jco.2005.23.16_suppl.3067

Citations

Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

Hobday, Timothy J. , Mahoney, M. R. , Erlichman, Charles , Lloyd, R, Kim, G., Mulkerin, Daniel , Fitch, Tom R., Donehower, Ross C. , Picus, Joel

A phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): A clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) Study

Erlichman, Charles , Goldberg, Richard M. , Mahoney, M. R. , Kabat, Brian, Huntington, Jefrey L., Sebo, Thomas J., Egner, James R., Pitot, Henry C., Sargent, Daniel J. , Kaufmann, Scott H.

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

Kozloff, M., Cohn, Allen Lee, Christiansen, N., Flynn, Patrick J. , Kabbinavar, Fairooz F. , Robles, Robert, Sarkar, Somnath , Hambleton, J., Yood, Marianne Ulcickas , Grothey, Axel

Cost-effectiveness projections of FOLFOX vs. IFL in first-line therapy of metastatic colorectal cancer in the context of the U.S. health care system

Hillner, Bruce E., Fuchs, Charles S. , Goldberg, Richard M. , Schrag, Deborah , Sargent, Daniel J.

Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)

Malik, Imtiaz A. , Hecht, J. Randolph, Patnaik, A., Croghan, Gary A., Navale, Lynn, MacDonald, Michael R. , Jerian, S., Meropol, Neal J. , Patnaik, Amita , Venook, Alan P. , Berlin, Jordan D.

Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chem

Rowland, Kendrith M. , Pitot, Henry C., Philip, P. A., Mitchell, Edith P. , Mailliard, J A, Goldberg, Richard M. , Sargent, Daniel J. , Alberts, Steven R.

Endpoints for Colon Adjuvant Clinical Trials (CACT): Recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials

Sargent, Daniel J.

Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity

Grothey, Axel, McLeod, H. L., Green, E. M., Ramanathan, Rajesh , Findlay, B., Goldberg, Richard M. , Green, E. M., Sargent, Daniel J. , Fuchs, C., Williamson, Stephen K.

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis

Arkenau, Hendrik‐Tobias , Kubicka, Stefan, Kretzschmar, Albrecht , Freier, Werner , Seufferlein, Thomas , Hinke, Axel , Porschen, Rainer, Schmoll, Hans‐Joachim , Graeven, Ullrich , Grothey, Axel

A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

Adjei, Alex A. , Mandrekar, Sumithra J. , Marks, Randolph S., Hanson, L., Aranguren, Dawn, Jett, James R., Simantov, Ronit, Croghan, Gary A., Schwartz, Brian E.